Penumbra Inc
NYSE:PEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Penumbra Inc
NYSE:PEN
|
US |
|
Saia Inc
NASDAQ:SAIA
|
US |
Intrinsic Value
The intrinsic value of Penumbra Inc (PEN) under the Base Case is 293.189 USD per share.
Compared with the current market price of 319.615 USD, the stock appears
Overvalued by 8% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Penumbra Does
Penumbra makes medical devices that doctors use to treat blood clots and other vascular problems. Its products include catheter-based systems for removing clots, embolization devices used to block blood flow in abnormal vessels, and tools for navigating and treating vessels in the brain and body. The company sells mainly to hospitals, outpatient procedure centers, and the physicians who perform these interventions.
- Headquarters
- United States of America US
- Employees
- 4 700
- IPO date
- Sep 18, 2015
Penumbra has no economic moat
Hospitals and specialist physicians can choose among competing clot-removal and neurovascular devices, and Penumbra says decisions depend on safety, effectiveness and price. Its name and manufacturing scale do not appear to stop established rivals from offering alternatives or discounts.
Read the full moat analysis
Revenue & Expenses Breakdown
Penumbra Inc
Earnings Waterfall
Penumbra Inc
The intrinsic value for Penumbra Inc (PEN) under the Base Case is 293.189 USD.
Compared with the current market price of 319.615 USD, the stock appears Overvalued by 8% .